Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's AOCI?
- Neurocrine Biosciences (NBIX) reported AOCI of $400K in Q1 2026.
- How has Neurocrine Biosciences's AOCI changed year-over-year?
- Neurocrine Biosciences's AOCI decreased by 95.6% year-over-year, from $9M to $400K.
- What is the long-term trend for Neurocrine Biosciences's AOCI?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's AOCI has grown at a 48.7% compound annual growth rate (CAGR), from $1.8M to $13.1M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Neurocrine Biosciences's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude